Other treatment options for patients with metastatic NSCLC who progress after platinum-based chemotherapy (second line and beyond) include pemetrexed and docetaxel [16] as well as anti-program cell death protein-1 (PD-1) inhibitors such as nivolumab, pembrolizumab and programmed cell death ligand-1, atezolizumab [10]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.